TLR-7／8激动剂作为疫苗佐剂的最新研究进展  

Progress of TLR-7/8 agonists as vaccine adjuvant

作　　者：周春雪[1] 李冬[1] 

机构地区：[1]中国农业科学院兰州兽医研究所家畜疫病病原生物学国家重点实验室农业部畜禽病毒学重点开放实验室国家口蹄疫参考实验室,兰州730046

出　　处：《免疫学杂志》2013年第6期527-530,共4页Immunological Journal

基　　金：“十二五”国家科技支撑计划项目(2013BAD12B00)

摘　　要：小分子TLR-7和TLR-8激动剂(agonist)具有很强的抗病毒与抗肿瘤性能,引起了科研人员的极大关注。最为重要的当属咪唑喹啉衍生物家族(imidazoquinoline),包括咪喹莫特(imiquimod),瑞喹莫特(resiquimod)等。通过对不同种类的咪唑喹啉衍生物的研究,TLR-7和TLR-8的多种新功能被揭示了出来。TLR-7/8介导对中心转录因子的调节,可以诱发炎性细胞因子和其他调节成分的产生,从而在抗病毒与抗肿瘤的免疫反应中起到重要作用。试验证实,咪唑喹啉衍生物与蛋白质疫苗、多肽疫苗和DNA疫苗协同作用后,诱发的免疫反应倾向Th1,同时产生大量的细胞因子及趋化因子,这使得其有可能成为一种新型的疫苗佐剂。越来越多的咪唑喹啉衍生物(imidazoquinoline)被研发出来,并且应用于试验及临床当中,为寻找一种新的、简单而安全的疫苗佐剂开辟了新思路。Small molecules TLR-7/8 agonists have potent antiviral and antitumor activity, which have drew a lot of attention. Imidazoquinoline is one of the most important agonists, including imiquimod, resiquimod, et al. More functions of TLR-7 and TLR-8 are revealed though the research of imidazoquinoline. TLR-7/8 mediate the regulation of central transcription factor NF-KB, resulting in production of inflammatory cytokines and other regulatory components, thus play critical roles in antivirus and antitumor immune response. Imidazoquinoline favors a Thl like response following the delivery of protein, peptide or DNA vaccine, and then induce a lot of cytokines and chemokines. All the experiments show that imidazoquinoline will be a new vaccine adjuvant. More imidazoquinolines are being developed and tried in clinical trials, which would provide a new choice for a new simple and safe adjuvant.

关 键 词：咪唑喹啉衍生物 咪喹莫特 瑞奎莫特 佐剂 

分 类 号：R392[医药卫生—免疫学]